Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

194 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA- and HRAS-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity.
Smith AE, Chan S, Wang Z, McCloskey A, Reilly Q, Wang JZ, Patel HV, Koshizuka K, Soifer HS, Kessler L, Dayoub A, Villaflor V, Adkins DR, Bruce JY, Ho AL, Perez CA, Hanna GJ, Gascó Hernández A, Saunders A, Dale S, Gutkind JS, Burrows F, Malik S. Smith AE, et al. Among authors: burrows f. Cancer Res. 2023 Oct 2;83(19):3252-3263. doi: 10.1158/0008-5472.CAN-23-0282. Cancer Res. 2023. PMID: 37339176 Free PMC article.
Mutated HRAS Activates YAP1-AXL Signaling to Drive Metastasis of Head and Neck Cancer.
Jagadeeshan S, Prasad M, Badarni M, Ben-Lulu T, Liju VB, Mathukkada S, Saunders C, Shnerb AB, Zorea J, Yegodayev KM, Wainer M, Vtorov L, Allon I, Cohen O, Gausdal G, Friedmann-Morvinski D, Cheong SC, Ho AL, Rosenberg AJ, Kessler L, Burrows F, Kong D, Grandis JR, Gutkind JS, Elkabets M. Jagadeeshan S, et al. Among authors: burrows f. Cancer Res. 2023 Apr 4;83(7):1031-1047. doi: 10.1158/0008-5472.CAN-22-2586. Cancer Res. 2023. PMID: 36753744 Free PMC article.
Evolutionary dynamics of tipifarnib in HRAS mutated head and neck squamous cell carcinoma.
Jagadeeshan S, Suryamohan K, Shin N, Mathukkada S, Boyko A, Melikhova D, Tsareva A, Yunusova L, Pravdivtseva E, Stupichev D, Shaposhnikov K, Peterson A, Bednyagin L, Shugaev-Mendosa E, Kessler L, Burrows F, Ho AL, Agrawal N, Pearson AT, Izumchenko E, Cole G, Elkabets M, Rosenberg AJ. Jagadeeshan S, et al. Among authors: burrows f. Oral Oncol. 2024 Feb;149:106688. doi: 10.1016/j.oraloncology.2024.106688. Epub 2024 Jan 13. Oral Oncol. 2024. PMID: 38219706
Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to venetoclax.
Rausch J, Dzama MM, Dolgikh N, Stiller HL, Bohl SR, Lahrmann C, Kunz K, Kessler L, Echchannaoui H, Chen CW, Kindler T, Döhner K, Burrows F, Theobald M, Sasca D, Kühn MWM. Rausch J, et al. Among authors: burrows f. Haematologica. 2023 Oct 1;108(10):2837-2843. doi: 10.3324/haematol.2022.282160. Haematologica. 2023. PMID: 37102614 Free PMC article. No abstract available.
Population pharmacokinetics of fluconazole in critically ill patients receiving extracorporeal membrane oxygenation and continuous renal replacement therapy: an ASAP ECMO study.
Novy E, Abdul-Aziz MH, Cheng V, Burrows F, Buscher H, Corley A, Diehl A, Gilder E, Levkovich BJ, McGuinness S, Ordonez J, Parke R, Parker S, Pellegrino V, Reynolds C, Rudham S, Wallis SC, Welch SA, Fraser JF, Shekar K, Roberts JA. Novy E, et al. Among authors: burrows f. Antimicrob Agents Chemother. 2024 Jan 10;68(1):e0120123. doi: 10.1128/aac.01201-23. Epub 2023 Dec 8. Antimicrob Agents Chemother. 2024. PMID: 38063399
Antimicrobial Exposures in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation.
Shekar K, Abdul-Aziz MH, Cheng V, Burrows F, Buscher H, Cho YJ, Corley A, Diehl A, Gilder E, Jakob SM, Kim HS, Levkovich BJ, Lim SY, McGuinness S, Parke R, Pellegrino V, Que YA, Reynolds C, Rudham S, Wallis SC, Welch SA, Zacharias D, Fraser JF, Roberts JA. Shekar K, et al. Among authors: burrows f. Am J Respir Crit Care Med. 2023 Mar 15;207(6):704-720. doi: 10.1164/rccm.202207-1393OC. Am J Respir Crit Care Med. 2023. PMID: 36215036 Clinical Trial.
Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1.
Fiskus W, Daver N, Boettcher S, Mill CP, Sasaki K, Birdwell CE, Davis JA, Das K, Takahashi K, Kadia TM, DiNardo CD, Burrows F, Loghavi S, Khoury JD, Ebert BL, Bhalla KN. Fiskus W, et al. Among authors: burrows f. Leukemia. 2022 Nov;36(11):2729-2733. doi: 10.1038/s41375-022-01707-w. Epub 2022 Sep 23. Leukemia. 2022. PMID: 36151141 Free PMC article. No abstract available.
194 results